6D·

Daiichi Sankyo enters my portfolio

After stumbling across the drug Datroway in an internal presentation, I took a closer look at the manufacturer. The result was a profitable BioTech company with a great pipeline, which is already profitable and growing strongly. As a small pearl, there is a small dividend on top.

Mr. Prompt and the dear @Raketentoni confirmed my assessment once again, so I couldn't keep my hands off it today and added it to my portfolio as a satellite.

I was still considering whether it would be the $DSNKY ADR or the original, but GPT convinced me of the original.

What do you think of $4568 (+1,37%) ?

06.03

Daiichi Sankyo

Comprado x125 em € 15,69

€ 1.961,25

8 Comentários

Raketentoni@Raketentoni

Congratulations and I'll post the analysis here again for everyone

He hasn't just dug up any old gaff, but the current "shooting star" of oncology.

Daiichi Sankyo (4568.T).
You've done your homework. The story about the breast cancer drug is true. We're talking about Enhertu (trastuzumab deruxtecan). This is the 'gold standard' in the medical community right now. Together with AstraZeneca, they are rolling up the market with it.
But as always, a great story does not make a good investment for my portfolio. Let's take a look at the books:
1. the core quality check (growth & substance)
The story: Enhertu is a money-printing machine. Sales are growing at double-digit rates, sometimes rapidly.
The figures: Daiichi is growing enormously. Sales growth > 20 % is not uncommon here. The operating margin is steadily improving as the high development costs are now bearing fruit.
My score: > 35 points.
Verdict: Pass with an asterisk. This is extremely high quality. Not a 'biotech gamble', but big pharma in growth mode.
2. the dividend check (the damper)
You say: 'There are dividends too'.
I say: 'Yes, but it's more of a tip'.
The current dividend yield is a meagre ~0.6% to 0.8%.
My limit: 3.5 %.
Verdict: Failed.
3. the valuation (the price of success)
Here I have to raise my finger. Since every analyst knows that Enhertu could become the best-selling drug by 2030, this is already heavily priced into the share price.
The P/E ratio is often over 40x.
You are already paying today for the success of 2028. If even one small study goes wrong or a patent dispute arises (which is commonplace in the pharmaceutical industry), the share price will plummet.
My conclusion for you, @Keineui:
You've found an excellent growth company here.
If you are looking for price gains and believe in Enhertu's dominance: buy/hold.
If you (like me) are looking for cash flow and dividends: Hands off. The yield is too low and the valuation too high.
I would tolerate it as an 'aggressive satellite' in the portfolio, but not as a basic investment for retirement.
Hilsen from Denmark,
Mister Prompt"

•

jkb92@jkb92

@Raketentoni gq and TR show a higher dividend yield. What is true?

••

Raketentoni@Raketentoni

@jkb92 does TR calculate them directly parallel to the course?

••

jkb92@jkb92

@Raketentoni with a little offset but actually already

••

Raketentoni@Raketentoni

@jkb92 I think that's down to the old payments, the share price and any prospects. 🤷 It remains to be seen, the decisive factor is that he has a great share.

•

Keineui@Keineui

@jkb92 In fact, the number after the decimal point is not really important to me.
But according to this source, it is:

As of March 2026, Daiichi Sankyo paid dividends totaling EUR 0.43 per share within the last 12 months. At the current share price of EUR 15.67, this corresponds to a dividend yield of 2.72%. The formula for calculating Daiichi Sankyo's dividend yield is: EUR 0.43 ÷ EUR 15.67 * 100 = 2.72%.

https://aktienfinder.net/dividenden-profil/Daiichi%20Sankyo-Dividende

By the way, Getquin also calculates the dividend yield on the basis of the current share price, so I would basically trust this information.

But there is still the currency risk anyway, so it doesn't really matter to me personally whether it's 2.2% or 2.8%.

•

Raketentoni@Raketentoni

@Keineui Now that's embarrassing - you totally got me there! 😳
As we say in Denmark: "Ashes on my head" (or rather powdered sugar on the smørrebrød).
You're absolutely right and I need to clean my glasses. I must have looked at an outdated column or confused the "yield" with another key figure. Thank you for being so attentive! That's exactly the level of quality we need here.
I'll correct it immediately:
Correction to Daiichi Sankyo (4568.T):
The mistake: I said ~0.6%. That was nonsense.
The reality (as of today):
Price: currently often oscillates around JPY 2,900 - 3,000 (after a correction from the highs).
Dividend: The forecast for the full financial year is around JPY 78 - 80 per share.
The real yield: 78 / 2900 = approx. 2.7 %.
New verdict for @Keineui:
This is a massive game changer!
With ~2.7% yield, Daiichi Sankyo is no longer a "flop" but a solid "hold/buy" candidate.
It is still just below my "sacred 3.5% limit" for the pure income portfolio.
BUT: For a growth stock (with Enhertu fantasy), a 2.7% dividend is extremely attractive. This is "growth with a safety net".
Please pass on my apologies to him. He made a better catch than I gave him credit for. Just goes to show: four eyes see more than two (especially when two of them are a bit older) 😉
Hilsen,
Mister Prompt

•

STFU Capital 闭嘴@STFUCapital

That’s an interesting one! Not among the big ones, so as a satellite, it might be a good option!

•